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Prolactin release is a side effect of antipsychotic therapy with dopamine antago-
nists, observed in rats as well as humans. We examined whether two semimecha-
nistic models could describe prolactin response in rats and subsequently be
translated to predict pituitary dopamine D2 receptor occupancy and plasma pro-
lactin concentrations in humans following administration of paliperidone or
remoxipride. Data on male Wistar rats receiving single or multiple doses of
risperidone, paliperidone, or remoxipride was described by two semimechanistic
models, the precursor pool model and the agonist–antagonist interaction model.
Using interspecies scaling approaches, human D2 receptor occupancy and plasma
prolactin concentrations were predicted for a range of clinical paliperidone and
remoxipride doses. The predictions were compared with corresponding observa-
tions described in literature as well as with predictions from published models
developed on human data. The pool model could predict D2 receptor occupancy
and prolactin response in humans following single doses of paliperidone and
remoxipride. Tolerance of prolactin release was predicted following multiple
doses. The interaction model underpredicted both D2 receptor occupancy and
prolactin response. Prolactin elevation may be deployed as a suitable biomarker
for interspecies translation and can inform the clinical safe and effective dose
range of antipsychotic drugs. While the pool model was more predictive than the
interaction model, it overpredicted tolerance on multiple dosing. Shortcomings
of the translations reflect the need for better mechanistic models.
Abbreviations
AAI, agonist–antagonist interaction model; D2, dopamine-2 receptor; ECu50, effec-
tive unbound concentration at half-maximal effect; KI, inhibition constant; PA,
paliperidone; PD, pharmacodynamics; PK, pharmacokinetics; PP, precursor pool
model; REM, remoxipride; RI, risperidone; RO, receptor occupancy, in %.
Introduction
Antipsychotics are the standard of care for schizophrenia,
and bring about their effects at least in part by binding to
central D2 receptors. Aside from central D2 receptor
antagonism, these drugs also bind to peripheral D2 recep-
tors located in the pituitary lactotrophs, which in turn
leads to plasma prolactin elevation (Peuskens et al. 2014).
This phenomenon is similar across species and thus pro-
lactin elevation may be deployed as a suitable biomarker
for interspecies translation (Ben-Jonathan et al. 2008).
While interspecies scaling of pharmacokinetic (PK) param-
eters is common in drug development, limited information
is available on prediction of pharmacodynamic (PD)
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parameters (Boxenbaum 1982; Lepist and Jusko 2004).
Zuideveld et al. (2007) were able to predict the hypothermic
and corticosterone releasing effects of flesinoxan and bus-
pirone in humans using a mechanistic PKPD model devel-
oped on rat data. Yet, such predictions are not always
possible, due to interspecies differences. Yassen et al. (2007a,
b) were able to translate the respiratory depressant effects
from rats to humans for buprenorphine, the same was not
the case for the antinociceptive effects. This is due to different
opioid mu receptor involved in the antinociceptive activity
and respiratory depressant effects. More recently, the PD of
prolactin following remoxipride administration was success-
fully extrapolated from rats to humans (Stevens et al. 2012).
We fitted two mechanism-based models, the precursor
pool (PP) model and the agonist– antagonist interaction
(AAI) model, to describe prolactin response in rats fol-
lowing single doses of risperidone (RI) or paliperidone
(PA), or two doses of remoxipride (REM) (Taneja et al.
2016a,b). While the AAI model predicted prolactin
response following multiple doses in rats better than the
PP model, the latter described the time course of receptor
occupancy better. To the best of our knowledge, the
interspecies scaling of prolactin response has been
described only for remoxipride (Stevens et al. 2012),
whereas rat to human scaling has not been published for
the AAI model. Given this background, the aim of this
work was to evaluate the predictive performance of either
model applying standard systems pharmacology inter-
species scaling approaches (Mager et al. 2009; Stevens
et al. 2012; Petersson et al. 2013). We further examine
the translatability of these PKPD models to predict pitu-
itary dopamine receptor occupancy (D2 RO) and plasma
prolactin response at steady-state concentrations of PA
and REM. The translational value of either model in pre-
dicting efficacy and safety in humans is compared with
published reports. The translational value of prolactin is
examined as well as its linkage to receptor occupancy.
The overarching aim of this work was to explore whether
interspecies translation of prolactin response could inform
dosing for subsequent first-in-human studies.
Materials and Methods
The experimental methods, as well as preclinical model
fitting have been presented elsewhere (Taneja et al. 2016a,
b). Here, we describe the models that were fitted and the
translational strategy for scaling the fitted models from
rats to humans.
Pharmacodynamic models
The PP model (Fig. S1) is an indirect response model
comprising of two hypothetical PD compartments,
represented by two differential equations describing the
turnover of prolactin in the lactotroph pool and in
plasma, respectively. The PP model hypothesizes tolerance
development following repeated doses of D2 antagonists
to be a result of depletion of the lactotroph pool (Movin-
Osswald and Hammarlund-Udenaes 1995). The turnover




¼ Rform  ð1þ PFÞ  Kbase  ð1þDEÞ  Cpool (1)
dCprl
dt
¼ Kbase  ð1þ DEÞ  Cpool  Kout  Cprl (2)
where Cpool and Cprl are the concentration of prolactin in
the lactotroph pool and plasma, respectively, Rform is the
zero-order rate constant for prolactin synthesis, Kbase is
the first-order rate constant of prolactin release from the
pool, and Kout is the first-order rate constant of elimina-
tion of prolactin from plasma.
Dopamine antagonists cause release of prolactin from
the pool, parameterized as drug effect DE given by the
following function:




where Emax is the maximum increase in the prolactin
release from the pool, ECu50 is the unbound drug concen-
tration at half-maximal effect, Cu is the unbound concen-
tration of the drug in plasma (unless otherwise
mentioned), and c is a slope factor. Once the final PP
model was developed, this model was modified to relate
drug effect to pituitary receptor occupancy (RO), rather
than to unbound drug concentration. Drug effect can be
represented in terms of RO as per the following expression:









RO50 is defined as RO for Cu = ECu50 (additional
details can be found in the supplemental section).
The second published model is the AAI model
(Fig. S2) which has been used to describe clinical data fol-
lowing administration of D2 antagonists to patients and
human healthy volunteers (Friberg et al. 2009b; Ma et al.
2010). This model describes the competition between the
concentrations of hypothetical (unobserved) dopamine
(DA) and the dopamine antagonist at the D2 receptor.
Prolactin stimulates the production of DA while the
hypothetical DA concentration inhibits prolactin release.
This model was originally proposed by Bagli and col-
leagues (Bagli et al. 1999) and subsequently modified
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(Friberg et al. 2009a) to additionally model the diurnal
variation in prolactin release.
The turnover of prolactin in plasma is described by:
dCprl
dt
¼Kin;0  1þDAs0ð Þ  1 DAs




 Kout  Cprl
(5)
where Kin,0 is the basal prolactin release rate, DAs0 and
DAs are the hypothetical scaled dopamine concentrations
at baseline and at time t, respectively, KI is the drug
potency parameter, and f(DIU) is a double cosine func-
tion to describe the diurnal variation in prolactin release
(Friberg et al. 2009b).




¼ KDA  DAs0  Cprl
Cprl;0
 c
 KDA  DAs (6)
KDA is the first-order rate turnover constant for hypo-
thetical dopamine and the ratio Cprl/Cprl,0 is a positive
feedback factor of prolactin on dopamine secretion, and c
the slope parameter of the positive feedback. In published
studies to date, the DAs0 parameter was fixed to 10,000,
as it could not be estimated (Friberg et al. 2009b). We
evaluated if the data was informative enough to be able
to estimate this parameter.
According to the theory of competitive receptor inter-
action, the receptor occupancy of the D2 antagonist drug




DAsþ CuKI þ 1
 100 (7)
and the receptor occupancy of dopamine is described by
ROdopamine ¼ DAs
DAsþ CuKI þ 1
 100 (8)
A step-by-step derivation of equations 7 and 8 can be
found in the accompanying supplemental material.
In vitro experimental KI values for all three com-
pounds in both rat and human species were available to
us (Taneja et al. 2016b). We estimated RO50 using both
the available experimental rat KI values as well as esti-
mated values obtained by fitting the AAI model to the
available data (Taneja et al. 2016a).
Rat-to-human translations
Predicted human unbound population plasma concentra-
tions were used as the driving force for the receptor
occupancy and prolactin response, and these were based
on human PK models for PA (OROS PA formulation)
and REM, previously described in the literature (Samtani
et al. 2011; Johnson 2012; Stevens et al. 2012). In case of
REM, the PK followed two-compartment first-order
kinetics, with the drug being administered intravenously.
The PK of the OROS PA formulation has been described
by a one-compartment model with sequential zero- and
first-order absorption (Johnson 2012).
For both models, the system-specific rate constants
(Rform, Kbase, and Kout in the PP model; Kin,0, Kout, and








where Khum and Krat refer to turnover constants in
humans and rats, respectively. BWhum and BWrat are the
respective body weights taken to be 70 kg and 0.28 kg. b
is the allometric exponent fixed to 0.25 (Lepist and
Jusko 2004; Anderson and Holford 2008).
Not all model parameters were scaled as described
above and for these, alternative strategies were applied as
explained hereunder, separately for each model.
PP model
The Emax was fixed for each compound to the value esti-
mated by Movin-Osswald and Hammarlund-Udenaes
(1995).
There are similarities between the neuroendocrine con-
trol of prolactin release between rats and humans, and
much of what is known about the underlying physiology
is based on studies in rodent models (Ben-Jonathan et al.
2008). Given this fact, the system-specific parameter RO50
was assumed to remain constant across compounds and
species and was fixed to the value obtained from the fits
to rat data.
AAI model
Two approaches were investigated to obtain the human
KIs. Petersson and colleagues have shown that human
in vitro experimental KI values for antipsychotics correlate
well with corresponding values estimated in vivo
(r2 = 0.94, P < 0.001) for five different antipsychotics,
using data from 16 clinical trials (Petersson et al. 2013). In
the first approach, these values were fixed to those from
in vitro experimental human values (Taneja et al. 2016b).
The second approach was based on integrating
estimated and experimental information given by the fol-
lowing function (Johnson 2012; Johnson et al. 2016):
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2017 | Vol. 5 | Iss. 6 | e00364
Page 3
A. Taneja et al. Translational Modeling of Prolactin Response
KIhum ¼ in vitro KIhum  KIrat
in vitro KIrat
(10)
where KIhum is the scaled human potency, in vitro KIhum
and in vitro KIrat are the experimental KI values for
human and rat, respectively, and KIrat is the estimated
potency parameter from rat data fits.
As DAs0 is a scaled concentration, no scaling was
attempted. Rather, the estimated value from rat data
(10.9) and the published estimated human value (10 000)
were both tested.
RO and prolactin profiles were predicted for both
models using the functions described earlier. For PA, RO
and prolactin responses for the following doses were pre-
dicted: 1.5, 3, 4.5, 6, 9, and 12 mg given once daily for
8 days. For REM, the chosen dose range was 50, 100, 150,
300, 450, and 600 mg once daily for 8 days. The chosen
dose ranges are based on the clinical therapeutic range
(Kane 1993). Farde and colleagues investigated an alterna-
tive dose regimen of 100 mg thrice daily and 200 mg
twice daily for REM in a PET study on healthy human
volunteers (Farde et al. 1988).
Using the model that best described RO and prolactin
response, we additionally predicted pharmacodynamic
responses with this alternative regimen over a period of
8 days. Rapid adaptation is a feature of the PP model and
hence, as an additional scenario for PA, we investigated
the effect of increasing the dosing interval to 7 days
between two consecutive doses (Mager and Jusko 2007).
Comparison of the predictions with
published human models
Model predictions were compared with data gleaned from
published literature. The benchmark data and the ratio-
nale for selection are described hereunder.
De Ridder (2005) developed a population PK model
using data from a four-way crossover trial in 32 healthy
subjects comparing single doses of an experimental con-
trolled-release formulation with an oral solution. Using
this model, a virtual population of 2000 patients was sim-
ulated and peak as well as average D2 RO were predicted.
We compared RO predictions from the translational PP
model with those of De Ridder. In vitro values for D2 RO
from literature (Johnson 2012; Johnson et al. 2016) were
overlaid on the predicted time course of RO we reported.
Average population plasma time course profiles of pro-
lactin were simulated for the original PP and AAI models
using the parameter estimates reported in literature
(Movin-Osswald and Hammarlund-Udenaes 1995; Friberg
et al. 2009b; Ma et al. 2010). These models were fitted to
human data and hence considered as benchmark models.
The Friberg model has a function for the diurnal rhythm,
which was identifiable in humans. In the current compar-
ison, predictions with this model are done without the
diurnal rhythm function. The model parameters used for
these simulations are presented in Table 1.
To the best of our knowledge, fitting of the PP model
to clinical PA data has not been published. In the current
analysis, we used the following expression to derive the
putative human EC50 of PA:
EC50;PA;hum ¼ EC50;REM;hum  in vitro KIPA;hum
in vitro KIREM;hum
(11)
where EC50,PA,hum and EC50,REM,hum are the human EC50s
for PA and REM, respectively, and in vitro KIPA,hum and
in vitro KIREM,hum are the corresponding human KIs.
Berwaerts et al. (2010) compared the prolactin releasing
potential of an ER preparation of paliperidone with that of
an IR formulation of risperidone. Given that we used PK
parameters from a similar formulation for our simulations,
we compared our model-predicted prolactin response with
that observed by Berwaerts and colleagues. The mean
observed plasma prolactin profiles for the 12 mg OROS PA
formulation from a published source were extracted using
WebplotDigitizer, and overlaid on the predicted prolactin
profiles for both models (Rohatagi 2014).
Software
Simulation was performed with NONMEM version 7.2.0
(Icon Development solutions, Hanover, MD, USA (Beal
et al. 2009)) in conjunction with PsN version 3.7.6 which
was used as a NONMEM interface (Lindbom et al. 2004).
R version 3.02 along with package Xpose 4 was used for
data manipulation, and statistical and graphical sum-
maries (Lindbom et al. 2004; R Core Team, 2015). Micro-
soft Excel 2007 was used for the simulations in the
validation exercise. WebplotDigitizer was used to extract
published data (Rohatagi 2014). Additional details on the
methods such as the experimental procedure and bioanal-
ysis, model parameterization and model building can be
found in the published literature (Taneja et al. 2016a).
Results
PP model predictions for PA
The predicted plasma PA concentration time course and
the corresponding RO time course for the OROS formu-
lation are depicted in Figure 1. PA OROS has a zero-
order release of more than 20 h and the half-life of PA is
~28 h (Johnson 2012; Rodriguez-Martinez and Quilo
2013). Steady state is thus reached at around 4 days after
dosing. There is little fluctuation between the minimum
2017 | Vol. 5 | Iss. 6 | e00364
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and maximum plasma concentrations. The same phe-
nomenon is predicted for the RO as well. The predicted
RO is in agreement with clinically observed central RO
following daily doses of 9 mg (Johnson 2012).
Figure 2 upper panels show the predicted prolactin
plasma time course over 8 days for the PP model as well
as the corresponding lactotroph prolactin time course.
Mean observations from a multiple dose study in healthy
volunteers receiving PA OROS 12 mg daily for 7 days
were extracted by digitization and are overlaid on the
plasma prolactin time course predictions (Berwaerts et al.
2010). In the lower panels, the prolactin lactotroph time
course predictions based on a healthy volunteer dataset
are overlaid on our predictions, showing good agreement
between both models on day 1 (Movin-Osswald and
Hammarlund-Udenaes 1995). Tolerance following
Table 1. Translated parameter estimates using the PP and AAI model as compared to published findings.
Movin-Osswald and
Hammarlund-Udenaes (1995)
Friberg et al. (2009b)
and Ma et al. (2010)
Our findings: translation
from rat to human
PP model
Rform (ngmL1h1) 16 26.5 12.41
Kbase (h
1) 0.105 0.11 0.0601
Kout (h
1) 1.3 2.09 1.671
Emax 66
2 NE 663
Slope (Lmg1) NE 4.08 NA
RO50 (%) NA NA 56.3
4
Cpool,0 (ngmL1) 1445 246 2076
Cprl,0 (ngmL1) 9.45 12.7 7.427
EC50_PA (lmol/L) 0.2768 NE NA
EC50_REM (lmol/L) 22 NE NA
Friberg et al. (2009b)
and Ma et al (2010)
Friberg et al. (2009b)
and Ma et al. (2010)
Our findings: translation
from rat to human
AAI model
Kin,0 (ngmL1h1) 5.099 7.339 7.591
Kout (h
1) 0.664 0.803 1.451
KDA (h
1) 0.156 0.134 0.991
DAs0 10,000 10,000 10.9
4
c 1.44 2.31 110
Cprl,0 (ngmL1) 7.67 9.13 5.239
KI_PA (nmol/L) (unbound) 1.0411 NE 8.4312
KI_REM (nmol/L) (unbound) NE 37.013 50.514
NE, not estimated; NA, not applicable.
1Calculated by allometric scaling (eq. 9) using values in the rat Taneja et al. (2016a), with BWhum = 70 kg, BWrat = 0.28 kg, and b = 0.25 Lepist
and Jusko (2004).
2Value reported for Emax model.
3Fixed for each compound to the value estimated in humans Movin-Osswald and Hammarlund-Udenaes (1995).
4Fixed for each compound to the value estimated in rats Taneja et al. (2016a).
5In the original pool model, mass balance was not taken into account.
6Calculated from Cpool,0 = Rform/Kbase.
7Calculated from Cprl,0 = Rform/Kout.
8See methods for scaling of EC50 (eq. 11): in vitro KIPA,hum = 2.08 nmol/L Taneja et al. (2016b), in vitro KIrem,hum = 165.75 nmol/L Taneja et al.
(2016b).
9Calculated from Cprl,0 = Kin,0/Kout.
10Fixed to 1 since slope factor c could not be estimated in rats (Taneja et al. 2016a).
11Calculated from KI = 1.96 ngmL1 Friberg et al. (2009b) and Ma et al. (2010) and protein binding 77.4% Taneja et al. (2016b) (molecular
weight PA = 426.48).
12See methods for scaling of KI (eq. 10) PA: in vitro KIrat = 2.74 nmol/L Taneja et al. (2016b), in vitro KIhum = 2.08 nmol/L Taneja et al. (2016b),
in vivo (rat) KI = 11.1 nmol/L Taneja et al. (2016a).
13Calculated from KI = 0.0687 mgL1 Friberg et al. (2009b) and Ma et al. (2010) and protein binding 80% Taneja et al. (2016b) (molecular
weight REM = 371.26).
14See methods for scaling of KI (eq. 10) REM: in vitro KIrat = 370.66 nmol/L Taneja et al. (2016b), in vitro KIhum = 165.75 nmol/L Taneja et al.
(2016b)), in vivo (rat) KI = 113 nmol/L Taneja et al. (2016a).
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multiple doses is predicted, as evident from the flat pro-
lactin concentration in Figure 2. However, by increasing
the dosing interval between successive doses to 7 days,
diminished tolerance is predicted, with the appearance of
a smaller peak on day 8 (Fig. 3).
PP model predictions for REM
The time course of the RO and corresponding prolactin
release are shown in Figure 4. RO is predicted to increase
nonlinearly. In contrast to PA, RO decreases during the
dosing interval, although not completely returning to
baseline. With increasing doses, the prolactin concentra-
tions are also predicted to increase nonlinearly. As in the
case of PA, tolerance of prolactin response is predicted
after the first dose, but to a lesser extent than for PA.
Partial recovery of the pool is predicted for doses up to
300 mg, although subsequent prolactin peak concentra-
tions are about 10% of those on day 1.
With altered dosing paradigms of 100 mg thrice daily
and 200 mg twice daily, respectively, peak RO was 90%
and 95%, with median levels being 83% (74–89%) and
89% (72–93%), respectively (Fig. S3). Figures in brackets
indicate the 5% and 95% range. With these dosing regi-
mens, complete pool depletion was predicted following
the first day of dosing.
For either drug, predictions were not sensitive to RO50
values of 56.2% or 28.7%, which are obtained when esti-
mated or in vitro values of KI were used, respectively.
Scaling the KI, as per equation 10, resulted in peak
plasma prolactin concentrations being 6% higher for
REM, while for PA, these were 30% lower.
AAI model predictions for PA
Figure 5 shows the predicted RO and prolactin concen-
trations with the mean observations overlaid. With a
DAs0 of 10.9 (estimated from the rat), predicted RO
was between 7% and 20% across the dose range. No tol-
erance is evident. It can be seen that the plasma pro-
lactin levels are underpredicted, while tolerance is
negligible.
1.5 3 4.5 6 12
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Figure 1. Predicted human plasma concentration profiles (left panel) and RO profiles (right panel) with the translational PP model following once daily
dosing of PA 1.5, 3, 4.5, 6, 12 mg/day for 8 days. Dashed lines (right panel) show the zone of observed experimental in vitro RO (Johnson 2012).
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AAI model predictions for REM
With a DAs0 of 10.9, predicted RO ranged between 20%
and 60%, the maximum being a little over 60% at the
highest dose of 600 mg daily (Fig. 6). The RO is lower
on day 8 as compared to day 1, for doses >300 mg.
This is due to the increased DAs which is found to be
higher at the time of dosing at day 8, when compared
to day 1 (DAs0). Predicted prolactin concentrations are
correspondingly about eightfold lower than those
reported by Movin-Osswald and Hammarlund-Udenaes
(1995) and tolerance is predicted as well at doses
>300 mg (Fig. 6).
Fixing the DAs0 parameter to the fitted parameter value
10.9 or to 10 000 as proposed by Friberg et al. (2009b)
affected the prediction of the RO of the antipsychotic
drugs about 1000-fold, with extremely low levels of RO
for a parameter value of 10 000. The predicted prolactin
concentrations were not sensitive to these wide variations
in this parameter value given that other parameters did
not change (data not shown). Scaled KIs increased the
Cmax of the predicted plasma prolactin by 20–30%.
Comparison of the predictions with
published literature
Table 1 shows the parameter estimates by our interspecies
scaling approach as compared to estimates by fitting of
human data as published in the literature. Scaled parame-
ters for both models were in the same ballpark, except for
KDA, which differed by almost one log order.
Figure 7 depicts the time course of the predicted pool
and plasma prolactin profiles using the original PP model
for PA (Movin-Osswald and Hammarlund-Udenaes
1995). These predictions are in agreement with those
using the interspecies scaling approach (Fig. 2), in that
pool depletion is predicted following the first dose of PA.
The peak concentrations are lower as compared to Fig-
ure 2. Both models predict tolerance following the first
dose of PA, although there are differences in its extent.
1.5 3 4.5 6 12
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Figure 2. Predicted human plasma prolactin profiles (upper panel) and lactotroph prolactin profiles (lower panel) with the translational PP model
following once daily dosing of PA 1.5, 3, 4.5, 6, 12 mg/day for 8 days. Blue dots in the right panel show the mean observed human plasma
prolactin profiles over 7 days (Berwaerts et al. 2010). Green dashed line in the lower panel is the predicted human lactotroph prolactin profiles
(Movin-Osswald and Hammarlund-Udenaes 1995).
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These differences are attributable to different values of the
potency parameter used in these simulations. In case of
the interspecies scaling approach (Fig. 2), the KI is
2.08 nmol/L, while for simulations with the Movin-
Osswald model, the EC50 was 0.276 lmol/L (eq. 11). In
Figure 8 the time course of prolactin in the lactotroph
and plasma following 8 daily oral doses of REM is
depicted, again using the original model (Movin-Osswald
and Hammarlund-Udenaes 1995). As compared to the
interspecies scaling approach, plasma prolactin profiles on
day 1 differ by up to twofold (Fig. 4). On day 1 these are
higher with the translational PP model, and lower on day
8, indicating that the translational PP approach predicts
tolerance to a greater extent compared to the Movin-Oss-
wald model. However, predictions with the Movin-Oss-
wald model also suggest that tolerance is predicted to a
lesser extent for REM (Fig. 8) as compared to PA
(Fig. 7). The prolactin predictions fluctuate as per the
plasma concentration levels for REM, while for PA, pro-
lactin concentrations remain at baseline level after the
first dose.
In Figure 9 (left panel) the time course of plasma pro-
lactin following PA administration is depicted using the
Friberg et al. (2009a) model without a diurnal rhythm
function. Prolactin levels with this model are predicted to
be 30% higher than those predicted by the translational
AAI model (Fig. 5). The plasma prolactin profile for
REM predicted with the Ma AAI model is depicted in the
right panel of Figure 9 (Ma et al. 2010). These predic-
tions are similar to those with the Movin-Osswald model
(Fig. 8) (Movin-Osswald and Hammarlund-Udenaes
1995). This is logical since both models were fitted by Ma
et al. (2010) to the same data. The corresponding transla-
tional AAI model underpredicts the prolactin concentra-
tions by almost fivefold, and no tolerance is predicted
(Fig. 6). The model parameters used for these compar-
isons are presented in Table 1 (PD) and Table S1 (PK).
Discussion
The PP model and the AAI model were comparable in
describing the rat data (Taneja et al. 2016a). In order to
1.5 3 4.5 6 12
























































































Figure 3. Effect of increase in dose interval on the predicted human plasma prolactin profiles with the translational PP model. Doses of PA 1.5,
3, 4.5, 6, 12 mg/day are administered on day 1 (left panel) and day 8 (right panel).
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investigate the translatability of these models, we first
investigated the best strategy to scale the model parame-
ters. We applied allometric approaches to scale system-
specific rate constants (Rform, Kbase, and Kout in the PP
model; Kin,0, Kout, and KDA in the AAI model) (Mager
et al. 2009). For the translational PP model, these scaled
parameters were comparable to those of the benchmark
PP models (Table 1). Our assumption that RO50 does not
require translation was based on the pharmacological
principle that the drug effect is dependent on RO, irre-
spective of the compounds, provided that these are full
antagonists with a similar mechanism of action. RO50 is a
single common denominator expressing the receptor
blockade required to produce half-maximal effect, allow-
ing using in vitro KI values to estimate the potency of
different compounds. A similar approach was applied to
link central D2 RO to efficacy and safety (Pilla Reddy
2012). Moreover, the hypothalamo-pituitary system
regulating prolactin release is similar, although the rat
dopaminergic system is somewhat more complex
(Ben-Jonathan et al. 2008). Interspecies scaling of model
parameters has been applied for the PP model to predict
the effect of varying the dosing interval between two suc-
cessive doses of REM on prolactin response (Stevens et al.
2012). In contrast, our focus was on predicting prolactin
response at a clinically relevant dose regimen. Stevens and
colleagues applied a sigmoidal function to describe a posi-
tive feedback of prolactin on its own synthesis. However,
such a function leads to model instability (Bakshi et al.
2016; Taneja et al. 2016a).
In case of the AAI model, the scaled turnover constant
for prolactin (Kout) and the baseline plasma levels (Cprl,0)
were in the human ballpark, but not the scaled turnover
constant for dopamine (KDA) (Table 1). Dopamine levels
could not be measured in the preclinical studies, which
would have provided a more rational basis for the trans-
lation. In published preclinical and clinical studies with
the AAI model to date, DAs0 has typically been assumed
to be 10 000, since higher values resulted in unacceptably
long runtimes (Friberg et al. 2009b). We fixed it to a




































































































50 100 150 300 450 600
600
600
0 5 10 15 20 25 0 5 10 15 20 25 0 5 10 15 20 25 0 5 10 15 20 25 0 5 10 15 20 25 0 5 10 15 20 25

































































































Figure 4. Predicted human RO profiles (upper panels) and plasma prolactin profiles (lower panels) with the translational PP model following once
daily dosing of REM 50, 100, 150, 300, 450, 600 mg/day for 8 days. Day 1 (left panels) and day 8 (right panels) profiles are depicted.
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more plausible value of 10.9, estimated from rat data.
Since this parameter is a system-specific parameter and a
rationale for interspecies scaling is lacking and the param-
eters is scaled as it is, we hypothesized that no further
scaling was necessary. In the absence of drug, the RO of
dopamine (eq. 8) would be 99.99% if the DAs0 were
taken as 10 000 but would be 91.6% if it is taken to be
10.9. In other words, in the absence of drug, the concen-
tration of free receptors available for interaction with the
drug is extremely low, which seems unlikely from a physi-
ological standpoint.
Petersson and colleagues have shown that in vitro
experimental human KI values are highly correlated with
corresponding estimates from population data (Petersson
et al. 2013). On the other hand, Johnson and colleagues
have proposed a scaling which normalizes estimated rat
in vivo Kd to in vitro KI values for rats and humans
(Johnson et al. 2016). Hence, we tested both the in vitro
KIs as well as the scaled values.
Plasma prolactin predictions for OROS PA with the
original Movin-Osswald PP model (Fig. 7) show
differences in peak concentrations with those of the trans-
lational PP model owing to different values of the
potency parameter used (Fig. 2). What is common, how-
ever, is that the pool does not recover sufficiently to out-
put subsequent plasma prolactin peaks following the first
dose.
For REM, in contrast, the predictions indicate a drop
in RO between doses (Fig. 4). The corresponding plasma
prolactin predictions show that following the first dose,
complete pool recovery does not occur and subsequent
peaks are considerably lower than those at day 1. Predic-
tions with the original Movin-Osswald model revealed
quantitative differences with respect to the translational
PP model. The first peak was lower (50 ngmL1 com-
pared to 120 ngmL1) and subsequent peaks were
higher, indicating quicker recovery of the pool (Fig. 8).
In a published PK study with REM, prolactin peak con-
centrations were in the range of 38–72 ngmL1 following
50 mg REM (Movin-Osswald et al. 1995). A second dose
after a dosing interval of 24 h results in a second peak
almost identical to the first dose. This means that the
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Figure 5. Predicted human RO profiles (left panel) and plasma prolactin profiles (right panel) with the translational AAI model following once
daily dosing of PA 1.5, 3, 4.5, 6, 12 mg/day for 8 days. Blue dots in the right panel show the mean observed human plasma prolactin profiles
over 7 days (Berwaerts et al. 2010).
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translational PP model overpredicts prolactin concentra-
tion on day 1 and underpredicts thereafter.
For the observation that subsequent peaks occur with
REM but not with PA, we found that this is attributable
to differences in kinetics, in particular their half-life. The
half-life of REM is ~5 h which allows at least partial
recovery of the pool in-between doses, whereas for OROS
PA the recovery period is longer, as depicted in Figure 3.
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Figure 6. Predicted human RO profiles (upper panels) and plasma prolactin profiles (lower panels) with the translational AAI model following
once daily dosing of REM 50, 100, 150, 300, 450, 600 mg/day for 8 days. Day 1 (left panels) and day 8 (right panels) profiles are depicted.
Figure 7. Predicted human lactotroph prolactin profiles (left panel) and plasma prolactin profiles (right panel) with the original PP model (Movin-
Osswald and Hammarlund-Udenaes 1995) following once daily dosing of PA 0, 1.5, 4.5, 12 mg/day for 8 days.
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Predicted pituitary RO for PA and REM showed closer
agreement with published literature as compared to
plasma prolactin levels. Predicted pituitary RO for PA
compared well with in vivo D2 RO based on modeling
and simulation of human data (De Ridder 2005). Also,
these predictions compared well with the findings of
Johnson who predicted human striatal D2 RO using a
physiology-based PKPD model and compared predictions
with observed data (Fig. 1) (Johnson 2012).
For REM, the predicted pituitary RO was between 80%
and 95% for the dose range of 50–600 mg per day, while in
PET studies in humans, striatal RO has been reported to be
60–80% (Klemm et al. 1996). Farde and von Bahr reported
73% and 71% striatal RO in human subjects dosed with
REM 100 mg thrice daily or 200 mg twice daily, respec-
tively (Farde and von Bahr 1990). For these dosing para-
digms, we predicted median RO of 83% (90% prediction
interval 74–89%) and 89% (72–93%), respectively.
RO and plasma prolactin concentrations were underpre-
dicted by the translational AAI model for both PA and
REM. These underpredictions were in the range of 5–70-
fold for RO and 2–5-fold for prolactin, indicative of an arti-
fact in the model wherein the predicted RO (eq. 7) could
not explain the predicted prolactin response. If DAs0 is
10 000 as has been done in preclinical and clinical publica-
tions till now (Friberg et al. 2009b; Ma et al. 2010; Peters-
son et al. 2012, 2013), D2 receptor occupancy by dopamine
is nearly 100%, even in the presence of the drug, implying
that D2 receptor occupancy by the antipsychotic drug is
very low. If this parameter is taken to be 10.9, as estimated
from rat data, predictions of RO were higher, but yet
remained far below reported occupancy levels. Fixing the
DAs0 to an arbitrary constant enables description of the
data, but limits the predictive ability and translatability of
the model. Prolactin predictions are not sensitive to wide
variations in the estimate of this parameter (Friberg et al.
2009b). The translational AAI model does not predict the
overwhelming tolerance to prolactin response predicted by
the translational PP model.
It should be clarified that central (striatal) RO usually
reported in literature and the pituitary RO are not always
comparable. Kohler and Karlsson-Boethius (1989) stated
Figure 8. Predicted human lactotroph prolactin profiles (left panel) and plasma prolactin profiles (right panel) with the original PP model (Movin-
Osswald and Hammarlund-Udenaes 1995) following once daily dosing of REM 50, 150, 300, 600 mg/day for 8 days.
Figure 9. Predicted human plasma prolactin profiles with the original AAI model following once daily dosing of PA 0, 1.5, 4.5, 12 mg/day for
8 days (left panel) (Friberg et al. 2009b) or following once daily dose of REM 50, 150, 300, 600 mg/day for 8 days (right panel) (Ma et al. 2010).
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that REM is equipotent for blocking receptors in the pitu-
itary and the brain. Kapur et al. (2000) showed that for
haloperidol, the narrow therapeutic window of pituitary
D2 RO cannot be reliably quantified with PET studies,
and there was no significant difference between striatal
and extrastriatal D2 RO. In case of lipophilic antipsy-
chotics, brain concentrations are in rapid equilibrium
with plasma concentrations, and they may not undergo
active transport during distribution in brain (Matsui-
Sakata et al. 2005). In a PET study to examine RO in
humans, it has been shown that 80% of the REM injected
peripherally passed through the blood–brain barrier
within minutes (Farde and von Bahr 1990). For com-
pounds with a higher blood barrier penetration, pituitary
and striatal ROs are comparable or are in a constant
ratio. Risperidone (and by extension paliperidone) does
not penetrate the blood barrier well due to active efflux
by P-glycoprotein, and hence a higher disassociation
between central and neuroendocrine effects can be
expected (Kapur et al. 2000).
The significance of predicting plasma prolactin lies in
its ability to inform clinical efficacy and extrapyramidal
side effects. The RO predicted by the translational PP
model is in the same ballpark as that reported in pub-
lished studies using imaging modalities (Farde and von
Bahr 1990; Klemm et al. 1996). Furthermore, a similar
approach has been used to predict central RO for PA and
RI, respectively (De Ridder 2005; Gomeni et al. 2013). In
a study in healthy volunteers dosed with 70 or 140 mg
REM intravenously thrice daily for 7 days, seven out of
eight subjects on the highest dose reported akathisia on
day 7 of the study (Farde et al. 1988).
Our simulations with the translational PP model pre-
dict a peak RO of >90% for 200 mg twice daily. It is
known that motor side effects appear at RO > 80%,
hence the translational PP model would have been able to
predict akathisia with this dose regimen.
The incidence of extra-pyramidal symptoms becomes
significantly higher than placebo beyond a dose of 6 mg
PA daily (De Ridder 2005). Figure 1 shows that RO at
this dose is ~85%, indicative of a conformance between
model predictions and published information.
While both models have been published earlier with clin-
ical data, we linked the prolactin time course to receptor
occupancy, enabling prediction of efficacy as well as safety.
This resulted in the models becoming system-specific and
independent of physico-chemical properties of the drugs.
In conclusion, while neither model could completely
predict prolactin responses in humans, the translational
PP model predicted prolactin response after a single dose
better than the AAI model. Prolactin pool depletion is a
feature of this model, which precludes reliable multiple
dose predictions. Pituitary D2 RO, however, was reliably
predicted and can be the basis for predicting efficacy and
motor side effects in humans. The translational AAI
model failed to accurately predict RO and plasma pro-
lactin. It is of translational value if an alternative
approach is applied, wherein system-specific parameters
are fixed based on published data and KIs derived from
in vitro experimental information (Petersson et al. 2013).
Based on our findings, we speculate on possible improve-
ments in the modeling approach for future research. In
case of the translational PP model, the main drawback is
the acute tolerance predicted. Here, alternative mecha-
nisms of tolerance described in literature could be evalu-
ated. In addition, we did not have receptor occupancy
data, which would have greatly improved the predictive
properties of the model, given that we hypothesized that
RO was the driver of the prolactin response, rather than
the drug concentrations. In case of the AAI model, mea-
sured dopamine concentrations would have provided
seminal insights as to the dopamine feedback loop, and
possibly led to alternative parametrizations of this path-
way. Our effort is a first step toward addressing the com-
plex challenge of interspecies scaling of PD for
antipsychotics. Shortcomings of the translations reflect
the need for better mechanistic models. For our proposed
strategy to be fully applicable to a real-life situation, it
would have to be integrated with physiology-based phar-
macokinetic (PBPK) models (Rostami-Hodjegan 2012).
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Figure S1. Precursor pool (PP) model as implemented by
Stevens et al. (2012), modified so as to parametrize drug
effect (DE) in terms of receptor occupancy (RO).
Figure S2. Agonist–antagonist interaction (AAI) model as
implemented by Friberg et al. (2009b).
Figure S3. Predicted RO profiles (left) and plasma pro-
lactin profiles (right) following 100 mg thrice daily (up-
per panels) or 200 mg twice daily (lower panels) of REM
for 8 days in humans with the translational PP model.
Figure S4. Predicted typical time course of PA, RI, REM
and corresponding observed plasma prolactin concentra-
tions following single IV dosing of RI (2 mg/kg), PA
(0.5 mg/kg), REM (4/8/16 mg/kg) or two doses of REM
(3.8 mg/kg).
Figure S5. Time course of predicted ROpituitary in rats for RI
2 mg/kg (left panels) and REM 3.8 mg/kg (right panels) with
the PP model (upper panels) and the AAI model (lower pan-
els), compared to peak ROpituitary (red dots) and central RO
(blue dots) reported by Kapur et al. (2002). Note: Kapur et al.
used amisulpiride which has similar potency to remoxipride.
Table S1. Human PK parameters used for predictions with
the PP and AAI models.
Table S2. Final parameter estimates for the pool model and
interaction model describing the time course of prolactin and
the effects of drug thereupon, including the results of a non-
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KI values were fixed to the values estimated from the interac-
tion model.
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